Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The demand for Antiviral Drugs in Indonesia has been on the rise in recent years.
Customer preferences: Indonesian customers have shown a preference for Antiviral Drugs due to the increasing prevalence of viral diseases in the country. The outbreak of diseases such as dengue fever, influenza, and Zika virus has contributed to the growing demand for Antiviral Drugs in the country.
Trends in the market: The Antiviral Drugs market in Indonesia has witnessed a significant growth in recent years. The market has been driven by the increasing prevalence of viral diseases in the country. The demand for Antiviral Drugs is expected to continue to rise in the future due to the growing awareness of the benefits of these drugs in treating viral diseases.
Local special circumstances: Indonesia is the world's fourth most populous country, and its population is expected to continue to grow in the future. The growing population is expected to contribute to the increasing demand for Antiviral Drugs in the country. Additionally, Indonesia is a tropical country, which makes it more susceptible to the outbreak of viral diseases.
Underlying macroeconomic factors: The Indonesian government has been investing heavily in the healthcare sector in recent years. The government's efforts to improve healthcare infrastructure and increase access to healthcare services have contributed to the growth of the Antiviral Drugs market in the country. Additionally, the growing middle class in Indonesia has contributed to the increasing demand for healthcare services, including Antiviral Drugs.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights